基于竞争风险模型探索术前间接胆红素/总胆红素比值在胃癌中的预后价值

doi:10.3969/j.issn.1009-976X.2024.06.002

岭南现代临床外科 ›› 2025, Vol. 24 ›› Issue (06): 347-353.DOI: 10.3969/j.issn.1009-976X.2024.06.002

基于竞争风险模型探索术前间接胆红素/总胆红素比值在胃癌中的预后价值

马明哲^1,2, 袁庶强³, 闵筱辉^1,2,*

1.中山大学孙逸仙纪念医院消化内科,广州 510120;
2.中山大学孙逸仙纪念医院深汕中心医院消化内科,广东汕尾 516621;
3.中山大学肿瘤防治中心胃外科,广东广州 510060

通讯作者: * 闵筱辉,Email：minxh@mail.sysu.edu.cn
基金资助:
广东省自然科学基金（2016A030313316）

Preoperative indirect bilirubin to total bilirubin ratio： a novel rognostic factor for gastric cancer based on competing risk model

MA Ming-zhe^1,2, YUAN Shu-qiang³, MIN Xiao-hui^1,2,*

1. Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China;
2. Department of Gastroenterology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Shanwei, Guangdong 516621, China;
3. Department of Gastric Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

Received:2024-12-03 Online:2024-12-20 Published:2025-01-14
Contact: MIN Xiao-hui, minxh@mail.sysu.edu.cn

摘要/Abstract

摘要： 背景胆红素,尤其是间接胆红素,除了作为一种代谢废物外,由于其内在的抗氧化特性在肿瘤发生发展中也有一定影响。胆红素与患者预后的关系在许多肿瘤中已有相应研究报道,但其在胃癌中的作用尚不明确。方法回顾性地收集2008~2023年在中山大学肿瘤防治中心和中山大学孙逸仙纪念医院深汕中心医院接受根治性或姑息性胃切除术的1245名胃癌患者,并使用Fine和Gray竞争风险模型评估临床病理因素和胆红素相关指标的预后意义。结果除了常规的间接胆红素、总胆红素外,建立了一个新的预后指标,间接胆红素与总胆红素比值（ITR）,以预测接受根治性或姑息性手术的胃癌患者预后。结果显示ITR大于0.69的患者预后相对较好（HR=0.72,95%CI：0.61-0.84;P<0.01）。结论本研究表明术前ITR可作为胃癌患者新的预后标志物。

关键词: 胆红素, 胃癌, 预后, 竞争风险模型

Abstract: Background Besides its adverse effect, bilirubin, especially indirect bilirubin, also serves as a potent antioxidant and could influence the formation and development of carcinoma. The correlation between bilirubin with clinical outcome has been widely validated in several malignancies, nevertheless, whether bilirubin is capable of being a prognosis indicator in gastric cancer remains disputable. Methods We retrospectively reviewed 1245 gastric cancer （GC） patients who received radical or palliative gastrectomy at Sun Yat-Sen University Cancer Center and Shenshan Medical Center,Sun Yat-Sen Memorial Hospital from 2008 to 2023. Fine and Gray competing risk model was conducted to evaluate prognostic significance of clinicopathological factors and bilirubin. Results We derived a novel index, Indirect Bilirubin to Total Bilirubin Ratio （ITR） and explored its role in predicting prognosis of GC patients with curative/palliative surgery by utilizing competing risk regression model. At first time, we found patients with ITR>0.69 had relatively better prognosis （HR, 0.72; 95%CI, 0.61-0.84; P<0.001）. Conclusion Our study indicated that preoperative ITR could act as an independent prognostic factor in GC.

Key words: bilirubin, gastric cancer, prognosis, competing risk model

中图分类号:

R735.2

马明哲, 袁庶强, 闵筱辉. 基于竞争风险模型探索术前间接胆红素/总胆红素比值在胃癌中的预后价值[J]. 岭南现代临床外科, 2025, 24(06): 347-353.

MA Ming-zhe, YUAN Shu-qiang, MIN Xiao-hui. Preoperative indirect bilirubin to total bilirubin ratio： a novel rognostic factor for gastric cancer based on competing risk model[J]. Lingnan Modern Clinics In Surgery, 2025, 24(06): 347-353.

参考文献

[1] Bray F, Laversanne M, Sung H, et al.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Nakamura Y, Watanabe J, Akazawa N, et al.ctDNA-based molecular residual disease and survival in resectable colorectal cancer[J]. Nat Med, 2024, 30(11): 3272-3283.
[3] Zhang Q, Xia T, Qi C, et al.High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma[J]. BMC Cancer, 2022, 22(1): 77.
[4] Niu Z, Yan B.Prognostic and clinicopathological effect of the prognostic nutritional index (PNI) in patients with cervical cancer: a meta-analysis[J]. Ann Med, 2023, 55(2): 2288705.
[5] Terazawa K, Ohashi T, Shibata H, et al.Immune-modified Glasgow prognostic score: A new prognostic marker for head and neck cancer[J]. Head Neck, 2022, 44(11): 2555-2563.
[6] Tian BW, Yang YF, Yang CC, et al.Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis[J]. Immunotherapy, 2022, 14(18): 1481-1496.
[7] Shimizu T, Lengalova A, Martinek V, Martinkova M.Heme: emergent roles of heme in signal transduction, functional regulation and as catalytic centres[J]. Chem Soc Rev, 2019, 48(24): 5624-5657.
[8] Fevery J.Bilirubin in clinical practice: a review[J]. Liver Int, 2008, 28(5): 592-605.
[9] Fargo MV, Grogan SP, Saguil A.Evaluation of Jaundice in Adults[J]. Am Fam Physician, 2017, 95(3): 164-168.
[10] Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance[J]. Science, 1987, 235(4792): 1043-1046.
[11] Baranano DE, Rao M, Ferris CD, Snyder SH.Biliverdin reductase: a major physiologic cytoprotectant[J]. Proc Natl Acad Sci U S A, 2002, 99(25): 16093-16098.
[12] Zucker SD, Horn PS, Sherman KE.Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer[J]. Hepatology, 2004, 40(4): 827-835.
[13] Zhao H, Shen J, Ye Y, et al.Validation of plasma metabolites associated with breast cancer risk among Mexican Americans[J]. Cancer Epidemiol, 2020, 69: 101826.
[14] Lacko M, Roelofs HM, Te Morsche RH, et al.Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer[J]. Int J Cancer, 2010, 127(12): 2815-2821.
[15] Brandon M, Baldi P, Wallace DC.Mitochondrial mutations in cancer[J]. Oncogene, 2006, 25(34): 4647-4662.
[16] Ziech D, Franco R, Georgakilas AG, et al.The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development[J]. Chem Biol Interact, 2010, 188(2): 334-339.
[17] Glorieux C, Liu S, Trachootham D, Huang P.Targeting ROS in cancer: rationale and strategies[J]. Nat Rev Drug Discov, 2024, 23(8): 583-606.
[18] Trachootham D, Alexandre J, Huang P.Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?[J]. Nat Rev Drug Discov, 2009, 8(7): 579-591.
[19] Li K, Lin H, Liu A, et al.SOD1-high fibroblasts derived exosomal miR-3960 promotes cisplatin resistance in triple-negative breast cancer by suppressing BRSK2-mediated phosphorylation of PIMREG[J]. Cancer Lett, 2024, 590: 216842.
[20] Zhang C, Deng Z, Wu J, et al.HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors[J]. J Clin Invest, 2024, 134(23):e181044.
[21] 罗远云, 王晓通, 黄海舸. Nrf2/HO-1信号通路对消化道恶性肿瘤影响的研究[J]. 中国医学创新, 2024, 21(13): 177-182.
[22] Pourhoseingholi MA, Ashtari S, Hajizadeh N, Zali MR. Metabolic Syndrome, Gastric Cancer Mortality and Competing Risk Survival Analysis[J]. EBioMedicine, 2017, 15: 4-5.
[23] 钱迪, 涂博祥, 陈枭, 等. 基于Fine-Gray竞争风险模型的小肝癌患者预后模型构建与验证[J]. 中华肿瘤防治杂志, 2023, 30(23): 1435-1443.

基于竞争风险模型探索术前间接胆红素/总胆红素比值在胃癌中的预后价值

Preoperative indirect bilirubin to total bilirubin ratio： a novel rognostic factor for gastric cancer based on competing risk model

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李伟凡, 黄松音. TRIM5与恶性肿瘤不良预后相关性及其在胰腺癌恶性表型中的作用研究[J]. 岭南现代临床外科, 2024, 24(05): 263-275.
[2]	郑彪, 陈旭, 钱均霖, 许宝石, 甄潮辉, 梁锐. RAD54B在肝细胞癌中的表达及对临床预后的影响[J]. 岭南现代临床外科, 2024, 24(04): 225-230.
[3]	任雪康, 朱少功, 夏云展. 肾小球滤过率与原发性胃腺癌临床分期及其预后的关系[J]. 岭南现代临床外科, 2024, 24(04): 244-248.
[4]	刘立强, 李文滨, 叶会霖. 增强CT细胞外体积分数预测胰腺癌术后患者预后[J]. 岭南现代临床外科, 2024, 24(03): 141-149.
[5]	罗婉蓉, 张文岳, 罗葆明. 基于血管生成相关lncRNAs的肝细胞癌预后风险模型的构建及验证[J]. 岭南现代临床外科, 2024, 24(01): 7-13.
[6]	林坤鹏, 巴明臣, 唐云强, 王嘉康, 林晓纯. FAM72基因家族与肝细胞癌预后及免疫浸润的相关性分析[J]. 岭南现代临床外科, 2024, 24(01): 14-25.
[7]	罗鸿程, 张嘉豪, 何朝辉. 基于DNA损伤修复基因的膀胱癌预后风险模型构建及其在免疫治疗效果预测中的应用[J]. 岭南现代临床外科, 2024, 24(01): 26-36.
[8]	吴文霞, 张萌. 代谢综合征对非三阴型乳腺癌预后的影响[J]. 岭南现代临床外科, 2024, 24(01): 49-53.
[9]	卢晓裕, 郑埕斌, 洪晓哲, 谢容明. 完全腹腔镜与腹腔镜辅助远端胃癌根治术的近期临床疗效对比：一项单中心前瞻性队列研究[J]. 岭南现代临床外科, 2023, 23(06): 455-459.
[10]	林锐, 李国盛, 党裔武, 杨达平, 曾能永, 孔晋亮, 陈罡. BIRC5 mRNA及蛋白表达水平在肺腺癌组织中的临床病理意义研究[J]. 岭南现代临床外科, 2023, 23(06): 490-497.
[11]	张博弘, 张祺. 基于铜死亡相关基因的胶质瘤预后模型构建[J]. 岭南现代临床外科, 2023, 23(05): 392-398.
[12]	袁杭, 倪恩德, 陈灵姣, 王声燕, 邬慧倩, 张伶俐, 何璋海, 卞丽娟. 伴不典型临床病理特征的硬化性肺细胞瘤[J]. 岭南现代临床外科, 2023, 23(05): 399-404.
[13]	蔡雷琴, 黄楚霖, 余君言, 孙侃, 严励, 王晓艺, 徐明彤, 张锦, 吴木潮, 胡宇坤, 任萌. 3例原发性甲状腺滤泡性淋巴瘤的临床分析及文献复习[J]. 岭南现代临床外科, 2023, 23(05): 418-423.
[14]	宋顺心, 郭硕浩. 加速康复外科理念与技术在胃肠外科中的应用研究[J]. 岭南现代临床外科, 2023, 23(04): 315-319.
[15]	黄锐钦, 何坤, 钱均霖, 罗启杰. 肝癌患者肝切除术后的预后危险因素分析：一项单中心研究[J]. 岭南现代临床外科, 2023, 23(03): 205-214.